Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.65 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | F7 | P08709 | 1/20 | 0.60 |
| ▸ | F3 | P13726 | 1/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15223730 | 0.89 | HRH4 (0.62) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL1842307 | 0.87 | SMAD3 (0.68) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL29415437 | 0.87 | SMAD3 (0.68) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL6513774 | 0.87 | PIN1 (0.61) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL3030827 | 0.86 | EIF4A3 (0.59) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL3498709 | 0.84 | EGFR (0.64) | PIN1SMAD3PLD2PLD1KMT2A | |
| SCHEMBL4554337 | 0.84 | PIN1 (0.54) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL3632014 | 0.83 | MMP2 (0.62) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL6515615 | 0.82 | PIN1 (0.59) | PIN1SMAD3KDM4EHPGDHSD17B10 | |
| SCHEMBL6517283 | 0.82 | HRH3 (0.59) | PIN1SMAD3KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787783-B2 | Heparanase inhibitors and use thereof | Beta Therapeutics Pty Ltd (AU) | 2023-10-17 | — | — | US | disclosed |
| WO-2023118961-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-29 | — | — | WO | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-22 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2725013-B1 | NOVEL HISTONE DEACETYLASE INHIBITOR OF BENZAMIDES AND USE THEREOF | SINOPHARM A THINK PHARMACEUTICAL CO LTD (CN) | 2018-08-22 | — | — | EP | disclosed |
| US-9428478-B2 | Piperazine derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-9278089-B2 | Method of treating HCV infection with a small molecule CHK2 inhibitor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-08 | — | — | US | disclosed |
| EP-1747021-B1 | SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES | SQUIBB & SONS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-1747021-B1 | SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES | SQUIBB & SONS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20050137140-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| WO-2005037860-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037860-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-02-03 | — | — | US | disclosed |
| EP-1497282-A2 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4 PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004101767-A2 | CBI ANALOGUES OF THE DUOCARMYCINS AND CC-1065 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1445250-A1 | NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| US-20040018986-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-29 | — | — | US | disclosed |
| WO-2003087092-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 - NS4 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190939-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | CD47, ENPP2, CD2 | PIN1 1185/4885SMAD3 1226/4885KDM4E 2459/4885 |
| US-20050026987-A1 | CBI analogues of the duocarmycins and CC-1065 | CCNI, SP1, DCK | PIN1 1289/4885SMAD3 2119/4885KDM4E 1508/4885 |
| US-20040018986-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | SERPINB1, PRSS1, SPINT2 | PIN1 173/4885SMAD3 2436/4885KDM4E 1073/4885 |
| US-11787783-B2 | Heparanase inhibitors and use thereof | HPSE, HEXD, ENGASE | PIN1 762/4885SMAD3 3213/4885KDM4E 2390/4885 |
| US-20050043304-A1 | Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same | TPSAB1, TPSB2, TPSD1 | PIN1 3079/4885SMAD3 373/4885KDM4E 1687/4885 |
| US-20050137140-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | PRSS1, SERPINB1, SPINT2 | PIN1 316/4885SMAD3 1628/4885KDM4E 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.